Top Page
Niagen Bioscience
(NASDAQ:NAGE)
Niagen Bioscience (NAGE) vs. SPDR S&P 500 ETF (SPY)
Niagen Bioscience Business Overview & Revenue Model
Niagen Bioscience Earnings Call Summary
Niagen Bioscience Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 124.71M | 99.60M | 83.57M | 72.05M | 67.45M | 59.26M |
| Gross Profit | 79.68M | 61.59M | 50.78M | 42.80M | 41.49M | 35.27M |
| EBITDA | 21.14M | 9.21M | -3.89M | -16.74M | -25.45M | -18.34M |
| Net Income | 20.43M | 8.55M | -4.94M | -16.54M | -27.13M | -19.93M |
Balance Sheet | ||||||
| Total Assets | 98.14M | 68.28M | 54.96M | 54.06M | 57.84M | 38.36M |
| Cash, Cash Equivalents and Short-Term Investments | 64.14M | 44.51M | 27.17M | 20.29M | 28.02M | 16.50M |
| Total Debt | 3.06M | 2.65M | 3.28M | 4.26M | 4.70M | 1.64M |
| Total Liabilities | 27.46M | 22.18M | 26.51M | 25.39M | 26.11M | 21.93M |
| Stockholders Equity | 70.68M | 46.09M | 28.46M | 28.67M | 31.73M | 16.42M |
Cash Flow | ||||||
| Free Cash Flow | 21.15M | 11.95M | 6.97M | -15.43M | -24.57M | -10.74M |
| Operating Cash Flow | 21.41M | 12.11M | 7.12M | -15.10M | -24.16M | -10.60M |
| Investing Cash Flow | -260.00K | -143.00K | -143.00K | -334.00K | -409.00K | -165.00K |
| Financing Cash Flow | 10.74M | 5.37M | -90.00K | 7.65M | 36.09M | 8.65M |
Niagen Bioscience Technical Analysis
Niagen Bioscience Risk Analysis
Niagen Bioscience Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
75 Outperform | $539.49M | 26.99 | 38.90% | ― | 36.04% | 1240.00% | |
63 Neutral | $830.15M | -4.02 | -65.10% | ― | ― | -5.18% | |
61 Neutral | $1.14B | -17.49 | -22.38% | ― | 2147.20% | -269.99% | |
56 Neutral | $1.62B | -1.55 | -98.13% | ― | -0.54% | -259.57% | |
54 Neutral | $1.01B | -2.30 | -53.89% | ― | 175.62% | 19.63% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | $829.19M | -1.70 | -49.06% | ― | -78.55% | 7.74% |
Niagen Bioscience Corporate Events
On December 16, 2025, Niagen Bioscience’s subsidiary ChromaDex, Inc. entered into an assignment agreement with Queen’s University Belfast that replaced earlier joint ownership and licensing deals and transferred QUB’s entire interest in a core portfolio of NR-related patents to the company. In exchange, Niagen agreed to structured payments including a one-time sum of about $1 million for accrued royalties through 2024, recurring annual payments from 2026 to 2038, and additional lump-sum payments in 2035 and 2038, while QUB provided a broad release from past royalty and other obligations. Announced publicly on December 22, 2025, the transaction makes Niagen the sole owner of foundational composition-of-matter and related patents covering the production, composition, and global commercial use of NR and its salt forms, consolidating what the company describes as the most comprehensive and defensible intellectual property position in the NAD+ industry and giving it greater financial, strategic and operational flexibility in developing, partnering and licensing its NAD+ precursor pipeline, including potential pharmaceutical applications.
The most recent analyst rating on (NAGE) stock is a Buy with a $7.00 price target. To see the full list of analyst forecasts on Niagen Bioscience stock, see the NAGE Stock Forecast page.
On November 6, 2025, Niagen Bioscience announced that its Board of Directors approved a share repurchase program authorizing the company to buy back up to $10 million of its common stock over the next 24 months. This move reflects the company’s belief in its investment value and represents a strategic use of capital. The repurchases will be conducted in compliance with applicable laws and market conditions, and the program may be modified or terminated at any time. This initiative is expected to impact the company’s market positioning and shareholder value positively.
The most recent analyst rating on (NAGE) stock is a Buy with a $12.00 price target. To see the full list of analyst forecasts on Niagen Bioscience stock, see the NAGE Stock Forecast page.
On November 4, 2025, Niagen Bioscience reported a 33% increase in net sales for the third quarter of 2025, reaching $34.0 million, driven by strong Tru Niagen® sales and improved e-commerce performance. The company also launched AboutNAD®, a digital platform for NAD+ research, and expanded its distribution network for Niagen Plus™ IV therapies, reinforcing its leadership in the NAD+ market. The company reaffirmed its full-year outlook for 25% to 30% net sales growth, highlighting its strategic initiatives and operational improvements.
The most recent analyst rating on (NAGE) stock is a Buy with a $23.00 price target. To see the full list of analyst forecasts on Niagen Bioscience stock, see the NAGE Stock Forecast page.
On October 6, 2025, Niagen Bioscience announced an increase in its full-year 2025 net sales outlook to 25% to 30% year-over-year growth, up from the previous forecast of 22% to 27%. This adjustment reflects the company’s confidence in its market position, particularly following the FDA’s reversal of rulings on the DSHEA drug preclusion rule related to NMN, which could enhance awareness of the NAD+ precursor market. Niagen Bioscience emphasizes the superiority of its Niagen product over NMN supplements, citing issues with NMN products infringing on its patent portfolio and failing to meet label claims. The company’s robust IP protection and focus on quality and efficacy position it strongly in the growing NAD+ supplementation market.
The most recent analyst rating on (NAGE) stock is a Hold with a $8.50 price target. To see the full list of analyst forecasts on Niagen Bioscience stock, see the NAGE Stock Forecast page.